An elite team led by Professor Tsai Ying-Chieh developed Neuralli, a medical-grade probiotic that has been a hot seller in the United States since its launch in 2022.
The research and development of probiotics has progressed through four distinct stages: the first generation focused on intestinal digestion, the second on immune regulation, the third on metabolic enhancement, and the fourth on neuropsychological functions. Bened Biomedical Co., Ltd. specializes in the development of functional, fourth generation probiotics, including neurologically active probiotics known as neurobiotics. One of the neurobiotic strains called PS128 regulates various neurotransmitters and “happy” hormones through the influence of the gut-brain axis, and thereby improves discomfort caused by neurological problems such as insomnia, depression and anxiety.
Owing to the substantial annual growth of PS128 in the global market, Bened Biomedical has not only successfully secured multi-national partnerships for the distribution of neurobiotic products but has also implemented a flexible strategy of local manufacturing and adaptation to regional needs. This approach has earned the trust of consumers across Europe and the United States. Consequently, Bened Biomedical has set its sights on expanding into the global Asian market in the latter half of 2023. We aim to gain visibility and establish connections with suitable partners, collaborating to share the benefits of medical-grade probiotics.